Expanded Table 2
Table 2. Study characteristics and overall effect for main outcome and total mortality for studies registered in ClinicalTrials.gov prior to publication
Acronym
Start Pub
Drug
Primary
Date First PO
Contract or Comparator Consort Industry
Year Year
Outcome
Registered specified
Cooperative
Funding
(PO)
Registry #
Agreement
ACCORD 2000 2010 Bld press
Composite Yes
Yes
standard
No
D
-BP
control meds
Non-fatal
therapy
MI, non-fatal
stroke, CVD
1999
death
NCT620
ACCORD 2000 2008 Intensive tx to Major or
Yes
standard
No
D
Yes
-Diabetes
target normal non-fatal MI,
therapy
glycated
non-fatal
hemoglobin
stroke, CVD
1999
levels
death
NCT620
Accord2000 2010 Simvastatin
Major non
Yes
standard
No
D
Yes
Lipid
+
fatal MI
therapy
fenofibrate
stroke or
(simvastatin)
CVD death
NCT620
1999
ACES
1998 2005 Azithromycin Composite Yes
Placebo
No
M
Yes
death from
CV,revacular
ization,hospit
1999
alization
NCT617
AFFIRM
1995 2002 AntiAll-cause
Yes
controlled
No
D
Yes
1999
arrhythmic
mortality
NCT556
regulation
AIM2005 2011 Niacin +
composite
Yes
Placebo
No
M&D
Yes
HIGH
statin
death plus
NCT1202
2005
events
89
ALLHAT- 1993 2002 Amlodipine
Fatal or nonYes
Active
Yes
M&D
Yes
1999
BP
fatal MI
NCT542
comparator
Financial
Disclosur
es
NR
Primary
Outcome
Total
mortality
Null
Null
CF
Null
Harm
CF
Null
Null
CF
Null
Null
CF
Null
Null
CF
Null
Null
CF
Null
Null
ALLHATDOX
ALLHATLLT
Alpha
Omega
1993
1993
2005
2000
2002
2010
ENRICHD 1995
2003
ERA
2000
IMMEDI
ATE
MAGIC
1994
2004
1998
2012
2002
PEACE
1995
2004
PREVEN
T
1998
2003
Doxazosin
Pravastatin
Omega-3
Fatty Acids
Antidepressants &
CBT
Estrogen +
medroxyprogr
esterone
Drug
intravenous
glucoseinsulinpotassium
Magnesium
Drug Angiotensinconvertingenzyme
(ACE)
inhibitors
Warfarin
Fatal or nonfatal MI
All cause
mortality
Fatal and
nonfatal
cardiovascul
ar
Death or
recurrent MI
NCT542
1999
NCT542
1999
NCT1274
52
NCT557
Mean
minimal
coronary
artery
diameter
Progression
of ACS to
MI
NCT549
NCT9150
7
30 day all
cause
mortality
Death from
CVD
NCT610
NCT558
Recurrent
venous
NCT614
Yes
Yes
Yes
Yes
(diuretic)
Active
comparator
Usual care
Yes
No
Yes
Yes
M&D
CF
Null
Null
Yes
M&D
CF
Null
Null
Placebo
Yes
D
NR
Null
Null
Yes
Usual care
Yes
D
NR
Null
Null
Yes
Yes
Placebo
No
D
NR
Null
Null
Yes
Yes
Placebo
Yes
D
CF
Null
Null
Yes
Yes
Placebo
Yes
No
NR
Null
Null
Yes
Yes
Placebo
No
M&D
CF
Null
Null
Yes
No
Placebo
No
D
CF
Benefit
Null
2005
1999
1999
2004
1999
1999
1999
thromboemb
olism
SANDS
2002 2008 Aggressive
Carotid
Yes
Standard
Yes
D
Yes
treatment with artery intimal
therapy
lipid and
medial
blood
thickness
pressure
NCT4742
2002
medications
4
SCD1997 2005 Amiodarone
Total
Yes
Placebo
No
M
Yes
HeFT
Mortality
NCT609
1999
WACS
1993 2007 Beta-carotene CVD death
Yes
placebo
Yes
D
No
1999
or events
NCT541
WAVE
1996 2002 Vitamin E and Change in
Yes
Placebo
Yes
No
Yes
C
minimum
luminal
1999
diameter
NCT555
WELL1995 2003 Estradiol+me Change in
Yes
Placebo
Yes
D
Yes
HART
droxyprogeste percent
1999
rone
stenosis
NCT559
WHI-E
1999 2004 Estrogen
CHD
Yes
Yes
placebo
Yes
D
1999
Incidence
NCT611
WHI-EP
1999 2002 Estrogen +
CHD
Yes
Yes
Placebo
Yes
D
1999
progestin
Incidence
NCT611
WHS1991 2005 Aspirin
Non-fatal MI
Yes
No
Placebo
No
D
ASA
or Stroke or
death from
1999
CVD
NCT479
WHS-E
1991 2005 Vitamin E
Events and
Yes
No
placebo
Yes
D
cardiac
1999
interventions. NCT479
NR= Not reported. NP = Not powered.,CF = Consulting Fees; M = Industry contributed some money; D = Industry provided pharmaceutical drugs
CF
Benefit
Null
CF
Null
Null
NR
Null
Null
NR
Null
Harm
CF
Null
Null
CF
Null
Null
CF
Harm
Null
CF
Null
Null
CF
Null
Null